Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Among authors: qu xd. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.
[Health Assessment of the Stream Ecosystem in Beijing, China].
Zhang YH, Qu XD, Peng WQ, Zhang M, Zhang HP, Du LF, Zhang SC. Zhang YH, et al. Among authors: qu xd. Huan Jing Ke Xue. 2023 Oct 8;44(10):5478-5489. doi: 10.13227/j.hjkx.202210340. Huan Jing Ke Xue. 2023. PMID: 37827765 Chinese.
Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis.
Zhang ZH, Hou SN, Yu JZ, Zhang W, Ma JQ, Yang MJ, Liu QX, Liu LX, Luo JJ, Qu XD, Yan ZP. Zhang ZH, et al. Among authors: qu xd. Front Oncol. 2023 Jan 19;12:1086095. doi: 10.3389/fonc.2022.1086095. eCollection 2022. Front Oncol. 2023. PMID: 36741718 Free PMC article.
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, Qu XD, Chen L, Chen Y, Li ML, Zhu JJ, Tang ZY, Zhou J, Fan J, Sun HC. Zhu XD, et al. Among authors: qu xd. Ann Surg Oncol. 2023 May;30(5):2782-2790. doi: 10.1245/s10434-022-12530-z. Epub 2022 Sep 30. Ann Surg Oncol. 2023. PMID: 36178565 Free PMC article.
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, Zhang ZH, Zhang X, Huang A, Tang M, Tian MX, Jiang XF, Huang R, Tao CY, Fang Y, Gao J, Wu XL, Zhou J, Fan J, Liu WR, Shi YH. Qu WF, et al. Among authors: qu xd. BJS Open. 2022 Sep 2;6(5):zrac114. doi: 10.1093/bjsopen/zrac114. BJS Open. 2022. PMID: 36125345 Free PMC article.
61 results